Compare Johnson & Johnson (JNJ) vs T1 Energy Inc. Common Stock (TE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs T1 Energy Inc. Common Stock — how do they compare? Johnson & Johnson trades at $255.28 (market cap $599.12B), while T1 Energy Inc. Common Stock trades at $2.81 (market cap $946.42M). The key difference: Johnson & Johnson is far larger — about 633× T1 Energy Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while T1 Energy Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| JNJ | TE | |
|---|---|---|
Market Cap | $599.12B | $946.42M |
Volume | 16,640,951 | 12,898,774 |
Sector | Health | Industrials |
52-Week High | $278.43 | $12.04 |
52-Week Low | $186.00 | $2.72 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $627.40B | $1.72B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →
